$
13. 43
+0.03
+0.2239%
$
1.71B Market Cap
9.3 P/E Ratio
0.56% Div Yield
842,600 Volume
1.06 Eps
$ 13.4
Previous Close 
Want to track HOPE and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Capricor: Rolling BLA Submission Of CAP-1002 To Get DMD Treatment Program Going
Capricor Therapeutics, Inc.'s rolling BLA submission of CAP-1002 for the treatment of patients with DMD, expected in Q3 of 2024. Top-line results from Cohort A of the phase 3 HOPE-3 study, using CAP-1002 for the treatment of patients with DMD, expected Q4 of 2024. Additional results from phase 2 HOPE-2 study, using CAP-1002 for patients with DMD, to be presented at the upcoming PPMD 30th Annual conference between June 27th - 29th of 2024.
Seekingalpha | 2 years ago
2026 © Marketlog. All Rights Reserved.
